The Weill Cornell Medicine Radioactive Drug Research Committee is responsible for the review of research protocols involving investigational or non-routine clinical uses of radioactive drugs without New Drug Applications (NDA) filed with the FDA or without Investigational New Drug (IND) numbers issued by the FDA in humans that are subject to 21 CFR 361.1 and will be conducted at Weill Cornell Medicine-NewYork Presbyterian.
The term “radioactive drug” is defined in 21 CFR 310.3(n) and includes a “radioactive biological product” as defined in 21 CFR 600.3.
Approval of a research study by the RDRC is based on assurance that a protocol must:
If your Human Subjects protocol requires RDRC review, submit the following documents to email@example.com:
Changes that could potentially impact the initial RDRC approval may include, but are not limited to changes in one of the following: age of subjects, patient population, radiation dose or models used to estimate radiation dose, wording in protocol consents related to administration of radiation, regimen for administration of radiation, and change or departure of the PI. Investigators are responsible for obtaining RDRC approval prior to initiating these changes, following the same submission process by using the amendment form.
In all cases of protocols conducted under the auspices of the RDRC, all amendments must be reviewed and approved by the RDRC and the RSC. The RDRC Chair may be consulted to assist the PI with determining the extent of the amendment.
For further assistance contact us at firstname.lastname@example.org.
It is important that the risk is communicated in an easily understood language. Most risk factors are derived from data involving uniform exposure of the whole body. However, most exposures to research subjects are limited to a part of the body or, in the case of radiopharmaceuticals, result in non-homogeneous exposure of the whole body.
|RDRC Forms & Policies||Contact RDRC|